Maik Hauschild

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai et al. · New England Journal of Medicine · 2012 · 528 citations

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Jens Huober, Gunter von Minckwitz, Carsten Denkert et al. · Breast Cancer Research and Treatment · 2010 · 289 citations

Tumor Biology, Breast Oncology, Medicine +10

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

B. Gerber, Sibylle Loibl, Holger Eidtmann et al. · Annals of Oncology · 2013 · 151 citations · Full text

Breast Oncology, Gbg 44, Geparquinto Study +10

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial

Lukas Schwentner, G Helms, Valentina Nekljudova et al. · The Breast · 2016 · 66 citations · Full text